News Markets Groups
USA | Europe | Asia | World| Stocks | Commodities
Sandoz recently announced that the EMA (European Medicines Agency) has accepted its application for a 100 mg/ml citrate-free formulation of its biosimilar HYRIMOZ (adalimumab).
Category: News and Media